AstraZeneca PLC says it remains committed to developing medicines across small molecules, biologics, vaccines, protein engineering and devices and that's what its future targeted business development strategy will pursue.
Britain's second-biggest drug maker has recently been selling mature products to buyers in efforts to focus on its central...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
